Company: IOBT
Filing Date: 2025-05-23
Form Type: S-3
Source: 0001193125-25-125831
Chunk: 7

Company: IO Biotech, Inc.
Filing Date: 2025-05-23
Form: S-3
Chunk 7
---
required to register the shares of Common Stock underlying the Class B Warrants and Class C Warrants within 30 days after the date of issuance of the applicable EIB Warrants.

The foregoing is only a summary of the terms of the Finance Contract, the Side Letter, the Warrant Issuance Agreement, the Warrants, and the Registration
Rights Agreement, does not purport to be complete and is qualified in its entirety by reference to the full text thereof, copies of each of which have previously been filed as exhibits to our filings with the SEC.

Implications of Being an Emerging Growth Company and Smaller Reporting Company

The Jumpstart Our Business Startups Act (the JOBS Act) was enacted in April 2012 with the intention of encouraging capital formation in the United States and
reducing the regulatory burden on newly public companies that qualify as emerging growth companies. We are an “emerging growth company” within the meaning of the JOBS Act. We may take advantage of certain exemptions from various public
reporting requirements, including the requirement that we provide more than two years of audited consolidated financial statements and related management’s discussion and analysis of financial condition and results of operations, and that our
internal controls over financial reporting be audited by our independent registered public accounting firm pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 (the Sarbanes-Oxley Act). In addition, the JOBS Act provides that an
“emerging growth company” can delay adopting new or revised accounting standards until those standards apply to private companies. We intend to take advantage of these exemptions until we are no longer an emerging growth company. We have
elected to use the extended transition period to enable us to comply with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (1) are no longer an emerging
growth company and (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our consolidated financial statements may not be comparable to companies that comply with new or revised
accounting pronouncements as of public company effective dates.

We will cease to be an emerging growth company upon the earliest of (1) the end of
the fiscal year following the fifth anniversary of our initial public offering; (2) the last day of the fiscal year during which our annual gross revenues are $1.235 billion or more; (3) the date on which we